


(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
07 May 2020 (07.05.2020)



WIPO | PCT



(10) International Publication Number
WO 2020/092618 A9

(51) International Patent Classification:

A61K 31/135 (2006.01) *A61K 31/165* (2006.01)
A61K 31/137 (2006.01) *A61K 31/495* (2006.01)
A61K 31/138 (2006.01) *A61K 31/496* (2006.01)
A61K 31/15 (2006.01) *A61P 25/28* (2006.01)
A61K 31/343 (2006.01) *A61P 25/24* (2006.01)
A61K 31/381 (2006.01) *A61P 25/22* (2006.01)
A61K 31/4468 (2006.01) *A61P 15/10* (2006.01)
A61K 31/4525 (2006.01)

(21) International Application Number:

PCT/US2019/058927

(22) International Filing Date:

30 October 2019 (30.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/752,990	30 October 2018 (30.10.2018)	US
62/812,366	01 March 2019 (01.03.2019)	US
62/837,915	24 April 2019 (24.04.2019)	US
62/856,312	03 June 2019 (03.06.2019)	US
62/905,708	25 September 2019 (25.09.2019)	US

(71) Applicant: **ACADIA PHARMACEUTICALS INC.**
[US/US]; 12830 El Camino Real, Suite 400, San Diego, CA
92130 (US).

(72) Inventors: **BURSTEIN, Ethan, S.**; 4168 Sturgeon Court,
San Diego, CA 92130 (US). **STANKOVIC, Srdjan, R.**;
15 Alexander Drive, Flemington, NJ 08822 (US). **DIRKS,**
Bryan; 502 Carnegie Center, Suite 300, Princeton, NJ
08540 (US). **FAVA, Maurizio**; Massachusetts General
Hospital, 55 Fruit Street, Bulfinch 351, Boston, MA 02114
(US). **OWEN, James, Randall**; 72 Knoll Drive, Princeton,
NJ 08540 (US). **DEKARSKE, Daryl**; 13958 Centella Way,
San Diego, CA 92130 (US).

(74) Agent: **KANEKO, Miho** et al.; Goodwin Procter LLP, 100
Northern Avenue, Boston, MA 02210 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the revised international search
report:

17 June 2021 (17.06.2021)

(15) Information about Correction:

see Notice of 17 June 2021 (17.06.2021)

(54) Title: METHODS OF TREATING DEPRESSION, ANXIETY AND SEXUAL DYSFUNCTION USING THE COMPOUND
PIMAVANSERIN

(57) Abstract: The disclosure provides, in part, a method of treating anxious distress with major depressive disorder in a patient in need thereof, comprising administering to the patient *N*-(4-fluorophenylmethyl)-*N*-(1-methylpiperidin-4-yl)-*N'*-(4-(2-methylpropyloxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof. Also provided herein is a method of treating depression in a patient in need thereof, wherein the patient is also suffering from Parkinson's disease, comprising orally administering to the patient 34 mg of *N*-(4-fluorophenylmethyl)-*N*-1-methylpiperidin-4-yl)-*N'*-(4-(2-methylpropyloxy)phenylmethyl)carbamide once daily, as well as methods for the treatment of a SSRI or SNRI- induced sexual dysfunction in a human subject.



WO 2020/092618 A9

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2019/058927

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/135 A61K31/137 A61K31/138 A61K31/15 A61K31/343
A61K31/381 A61K31/4468 A61K31/4525 A61K31/165 A61K31/495
A61K31/496 A61P25/28 A61P25/24 A61P25/22 A61P15/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/112927 A1 (ACADIA PHARM INC [US]; WEINER DAVID M [US] ET AL.) 1 December 2005 (2005-12-01)	1-3,5,7, 8,11-14, 24,55, 57-59, 69-72, 78,79
Y	abstract claims 3,25-27,29,30,32 ----- -/--	1-3,5,7, 8,11-14, 24,55, 57-59, 69-72, 78,79



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 January 2020

Date of mailing of the international search report

23/01/2020

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Langer, Oliver

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2019/058927

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/039460 A2 (ACADIA PHARM INC [US]; HACKSELL ULI [US]; MCFARLAND KRISTA [US]) 26 March 2009 (2009-03-26)	1-3,5,7, 13,55, 57, 69-72, 78,79
Y	abstract paragraph [0063] - paragraph [0064]; claims 1,30	1-3,5,7, 13,55, 57, 69-72, 78,79
Y	----- WO 2008/116024 A2 (ACADIA PHARM INC [US]; PETERS PERRY [US] ET AL.) 25 September 2008 (2008-09-25) abstract paragraph [0194] - paragraph [0215]; example 7	1-3,5,7, 8,11-14, 24,55, 57-59, 69-72, 78,79
X,P	----- MAURIZIO FAVA ET AL: "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY)", THE JOURNAL OF CLINICAL PSYCHIATRY, vol. 80, no. 6, 24 September 2019 (2019-09-24), XP055656719, DOI: 10.4088/JCP.19m12928 the whole document -----	1-115

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2019/058927

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005112927 A1	01-12-2005	AU 2005244982 A1 CA 2567704 A1 EP 1750705 A1 EP 2283841 A1 JP 2008500390 A US 2005261278 A1 US 2005288328 A1 US 2009155389 A1 WO 2005112927 A1	01-12-2005 01-12-2005 14-02-2007 16-02-2011 10-01-2008 24-11-2005 29-12-2005 18-06-2009 01-12-2005
-----	-----	-----	-----
WO 2009039460 A2	26-03-2009	AU 2008302079 A1 CA 2700331 A1 DK 2200610 T3 EP 2200610 A2 HU E037639 T2 JP 2010540454 A NO 2200610 T3 SI 2200610 T1 US 2009082388 A1 US 2014349976 A1 WO 2009039460 A2	26-03-2009 26-03-2009 23-04-2018 30-06-2010 28-09-2018 24-12-2010 09-06-2018 29-06-2018 26-03-2009 27-11-2014 26-03-2009
-----	-----	-----	-----
WO 2008116024 A2	25-09-2008	AU 2008228833 A1 CA 2681506 A1 CN 101677971 A DK 2134330 T3 EP 2134330 A2 ES 2423485 T3 HR P20130713 T1 JP 2010522198 A PL 2134330 T3 US 2009053329 A1 US 2013143901 A1 US 2015231126 A1 WO 2008116024 A2	25-09-2008 25-09-2008 24-03-2010 05-08-2013 23-12-2009 20-09-2013 30-09-2013 01-07-2010 31-10-2013 26-02-2009 06-06-2013 20-08-2015 25-09-2008
-----	-----	-----	-----